Platinum-Sensitive Recurrent Ovarian Cancer
Showing 1 - 25 of >10,000
Recurrent Ovarian Cancer Trial in Pittsburgh (CPI-0209, carboplatin)
Not yet recruiting
- Recurrent Ovarian Cancer
-
Pittsburgh, PennsylvaniaMagee-Womens Research Institute / UPMC Magee Womens Hospital
Jul 3, 2023
Recurrent Ovarian Cancer Trial in Shanghai (Fuzuloparib Combination with Bevacizumab)
Not yet recruiting
- Recurrent Ovarian Cancer
- Fuzuloparib Combination with Bevacizumab
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Cente
Apr 14, 2023
Ovarian Cancer Trial (Aribulin;carboplatin;bevacizumab)
Not yet recruiting
- Ovarian Cancer
- (no location specified)
Jul 20, 2023
Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer Trial in Durham, Oklahoma
Recruiting
- Recurrent Ovarian Cancer
- +6 more
- Oregovomab
- Niraparib
-
Durham, North Carolina
- +2 more
Jul 26, 2022
Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV Trial in Seoul (Oregovomab, Bevacizumab,
Recruiting
- Ovarian Cancer by FIGO Stage
- +2 more
- Oregovomab
- +3 more
-
Daegu, Korea, Republic of
- +5 more
Oct 20, 2022
Ovarian Cancer Trial in Chongqing (fluzopanib and bevacizumab)
Recruiting
- Ovarian Cancer
- fluzopanib and bevacizumab
-
Chongqing, Chongqing, ChinaChongqing Cancer Hospital
Sep 19, 2022
Carcinoma, Ovarian Epithelial Trial in Hidaka (pembrolizumab, olaparib, bevacizumab)
Recruiting
- Carcinoma, Ovarian Epithelial
- pembrolizumab
- +5 more
-
Hidaka, Saitama, JapanSaitama Medical Uiversity International Medical Center
Apr 25, 2022
Ovarian Cancer, Malignant Tumor of Uterus Trial in New York (Sacituzumab, Cisplatin)
Not yet recruiting
- Ovarian Cancer
- Malignant Neoplasm of Uterus
-
New York, New YorkIcahn School of Medicine at Mount Sinai Division of Hematology a
Sep 14, 2023
Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor Trial in Seoul
Recruiting
- Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
-
Seoul, Korea, Republic ofYonsei University College of Medicine
Jul 6, 2021
Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor Trial
Active, not recruiting
- Fallopian Tube Endometrioid Tumor
- +13 more
- Olaparib
- Tremelimumab
-
Orange, California
- +19 more
Jan 10, 2023
Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Aurora (Mirvetuximab Soravtansine, Olaparib)
Not yet recruiting
- Ovary Cancer
- +2 more
- Mirvetuximab Soravtansine
- Olaparib
-
Aurora, ColoradoUniversity of Colorado Hospital
May 30, 2023
Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer Trial in Los Angeles (Simvastatin 40mg)
Recruiting
- Recurrent Ovarian Cancer
- Platinum-sensitive Ovarian Cancer
- Simvastatin 40mg
-
Los Angeles, CaliforniaCedars Sinai Medical Center
Apr 21, 2022
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine, Carboplatin)
Not yet recruiting
- High Grade Ovarian Cancer
- +2 more
- Mirvetuximab soravtansine
- Carboplatin
- (no location specified)
Jul 11, 2022
Ovarian Cancer Trial in China (Pamiparib capsule, Placebo capsule)
Active, not recruiting
- Ovarian Cancer
- Pamiparib capsule
- Placebo capsule
-
Hefei, Anhui, China
- +27 more
Aug 18, 2022
Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer Trial in Seoul (Olaparib-Pembrolizumab-Bevacizumab)
Enrolling by invitation
- Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer
-
Seoul, Korea, Republic ofYonsei Severance Hospital
Apr 14, 2021
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab)
Recruiting
- Ovarian Cancer
- +2 more
- Mirvetuximab soravtansine plus Bevacizumab
- Bevacizumab
-
New Orleans, Louisiana
- +3 more
Dec 16, 2022
Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer Trial in France (OSE2101, Pembrolizumab 25 MG/ML [Keytruda])
Recruiting
- Platinum-sensitive Ovarian Cancer
- Relapsed Ovarian Cancer
- OSE2101
- Pembrolizumab 25 MG/ML [Keytruda]
-
Angers, France
- +27 more
Jul 25, 2022
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal
Active, not recruiting
- Platinum-Resistant Fallopian Tube Carcinoma
- +11 more
- Aldesleukin
- +3 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jul 13, 2022
High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Cambridge (Upifitimab rilsodotin,
Recruiting
- High Grade Serous Ovarian Cancer
- +2 more
- Upifitimab rilsodotin
- Placebo
-
Phoenix, Arizona
- +40 more
Jan 25, 2023
Bespoke ctDNA Assay for Recurrence and Treatment Response
Recruiting
- Ovarian Cancer
- platinum-sensitive EOC
- platinum-resistant and rEOC
-
Shanghai, Shanghai, ChinaHao Wen
Jul 5, 2022
Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in
Not yet recruiting
- Ovarian Clear Cell Adenocarcinoma
- +14 more
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140
- +4 more
-
Buffalo, New York
- +1 more
Dec 16, 2022
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Australia (ATX-101 + Carboplatin + Pegylated
Recruiting
- Ovarian Cancer
- +3 more
- ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)
-
Blacktown, New South Wales, Australia
- +5 more
Nov 9, 2022
Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma Trial in United
Active, not recruiting
- Metastatic Fallopian Tube Carcinoma
- +11 more
- Berzosertib
- +4 more
-
Phoenix, Arizona
- +13 more
Dec 2, 2022